FMC Corporation has seen a notable shift in the short-selling picture this week — the aggressive positioning that defined June has started to unwind, even as the broader debate between bears and options bulls remains unresolved ahead of the July 29 earnings date.
The short interest story has changed direction. After climbing to over 21 million shares through late June, short interest has pulled back to 19.7 million shares — roughly 15.8% of the free float, down about 2% on the week. That is still a heavily shorted name by any measure, but the recent peak appears to have been June 30, when short interest briefly touched 21.1 million shares. The ORTEX short score reflects the same easing: it dropped from a spike of 71.0 on June 30 back to 59.4 as of July 7, retreating to where it was before last week's surge. Bears are trimming, not piling in further.
The borrow market tells the same story, and the reversal here is dramatic. Availability — how much room remains in the lending pool relative to shares already borrowed — has jumped to 648% from just 157% a week ago. For context, availability was above 1,000% through most of June before the June 30 spike compressed it to its tightest point of the past year. It has now recovered sharply, well back into normal territory. Cost to borrow has also eased, falling 34% on the week to 0.58%, unwinding much of the spike that accompanied the short buildup. The borrow market, in short, has loosened considerably. Options traders remain positioned for upside: the put/call ratio is 0.31, close to its 52-week low of 0.30 and still running well below its 20-day average of 0.35, with a z-score of -1.4. That bullish options lean has held firm for several sessions running.
The Street sits squarely in the middle. The consensus mean price target is $16.13, implying roughly 39% upside from the current $11.59 — but the direction of recent analyst action is cautious. Citigroup cut its target to $14 from $17 in late June, maintaining a Neutral rating, even after lifting it post-Q1 results in May. Most other recent moves from RBC, JPMorgan, and Wells Fargo were modest upward revisions following the prior earnings print, but none flipped to a conviction Buy. The one standout is Goldman Sachs, which carries a Buy and a $21 target. Valuation multiples offer some support for the bulls: the P/E has compressed to 5.8x, down more than one full turn over the past month, while EV/EBITDA at 7.0x is broadly unchanged. The bear case centres on persistent price pressure from Brazil competition and below-consensus Q2 guidance; bulls point to management's $600 million second-half EBITDA target and anticipated Latin America seasonal recovery. The EPS surprise factor score of 97 — the best in its cohort — suggests the company has a habit of clearing the bar when it matters.
The institutional flow adds an interesting wrinkle. BlackRock reported a 3.3-million-share increase in its holding as of June 30, lifting its stake to 18.7 million shares and roughly 15% of the company. That is a meaningful addition at a time when short sellers were aggressively building. CEO Pierre Brondeau sold 34,177 shares on June 11 at $10.80, a modest but notable transaction at a price below the current level. The net insider picture over 90 days is a small positive — net buying of around 55,000 shares — but the CEO sale and the magnitude of the short position are the harder signals to dismiss.
Among peers, CTVA gained 4% on the week and NTR added 6.5%, while OLN was broadly flat. FMC's 0.8% weekly gain leaves it lagging the agricultural chemicals group again. With the July 29 earnings print now three weeks out, the key question is whether the short unwind is a pre-earnings cover trade or the start of a genuine re-rating — and whether management's confident H2 EBITDA language holds up against what has been a stubborn pricing headwind in Brazil.
See the live data behind this article on ORTEX.
Open FMC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
FMC Corporation enters the final days of Q2 with its most aggressive short positioning in years — and the borrow market tightening at a pace that makes the setup genuinely interesting ahead of late-July earnings. The…
FMC Corporation heads into its April 30 Q1 earnings call with a notable divergence: short sellers have been covering aggressively, yet the stock keeps falling. Short interest tells the most striking story into this…
